Inclusion Criteria:

          -  Subjects must have histologically or cytologically confirmed non-small cell lung
             cancer (NSCLC)

          -  All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II &
             IIIA (N2 negative); IIIA (N2+), IIIB (N3+)

          -  Patients must have stable disease at the time of enrollment

          -  Women and men at least 18 years of age

          -  ECOG performance status 0-1(Appendix A)

          -  Subjects must be within 4 to 12 weeks of standard of care treatment for their
             particular stage of disease

          -  Subjects must have acceptable organ and marrow function as defined below:

               -  Leukocytes > 3,000/µL

               -  Absolute Neutrophils > 1,500/µL

               -  Hemoglobin > 10 g/dL

               -  Platelets > 100,000/µL

               -  Total Bilirubin within normal institutional limits

               -  Creatinine within normal institutional limits OR

               -  Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and
                  ALT with alkaline phosphatase within < 1.5 times upper limit of normal

          -  The effects of a MUC1vaccine on the developing human fetus at the recommended
             therapeutic dose are unknown. For this reason, men and women of childbearing potential
             must be willing to use effective contraception (hormonal barrier method of birth
             control; abstinence) while on study treatment and for at least 3 months thereafter.
             Should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately

        Exclusion Criteria:

          -  Subjects may not be receiving any other investigational agents

             - No history of prior malignancy, except for non-melanoma skin cancer

          -  Any positive ANA titer above 1:160, even in an asymptomatic individual. Note:

        Weakly positive ANA defined as ANA titers up to 1:160 maximum (≤ 1:160) will be acceptable
        in an asymptomatic individual who is otherwise eligible for the study. No prior vaccine
        therapy

          -  Known Hepatitis B on immunomodulators (i.e. interferon)

          -  Known Hepatitis C on immunomodulators (i.e. interferon)

          -  No prior vaccine therapy

          -  Patients may not be receiving any steroids or other anti-immune therapy at the time of
             registration.

          -  Subjects must not be more than 12 weeks from standard of care treatment for their
             particular stage of disease

          -  Subjects must not have post-obstructive pneumonia or other serious infection at the
             time of registration or other serious underlying medical condition that would impair
             the ability of the subjects to receive protocol treatment

          -  Prior resection of lung cancer is allowed, if at least five years have elapsed between
             previous resection and registration

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study. Women of childbearing potential must have
             a negative pregnancy test

          -  Subjects with immune deficiency are not expected to respond to the vaccine. Therefore,
             known HIV-positive patients are excluded from the study

          -  Subjects with a history of known autoimmune disease are excluded from this study